Patients with FGF23-related hypophosphatemic rickets/osteomalacia do not present with left ventricular hypertrophy

References

• Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19:429–435.
   PubMed Web of Science ®Google Scholar
• Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770–774.
   PubMed Web of Science ®Google Scholar
• Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem. 2006;281:6120–6123.
   PubMed Web of Science ®Google Scholar
• Shigematsu T, Kazama JJ, Yamashita T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis. 2004;44:250–256.
   PubMed Web of Science ®Google Scholar
• Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79:1370–1378.
   PubMed Web of Science ®Google Scholar
• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–1305.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Benedetto FA, Mallamaci F, et al. Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients. J Am Soc Nephrol. 2004;15:1029–1037.
   PubMed Web of Science ®Google Scholar
• Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011;121:4393–4408.
   PubMed Web of Science ®Google Scholar
• Grabner A, Amaral AP, Schramm K, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy. Cell Metab. 2015;22:1020–1032.
   PubMed Web of Science ®Google Scholar
• Unsal A, Kose Budak S, Koc Y, et al. Relationship of fibroblast growth factor 23 with left ventricle mass index and coronary calcificaton in chronic renal disease. Kidney Blood Press Res. 2012;36:55–64.
   PubMed Web of Science ®Google Scholar
• Knap B, Veceric-Haler Z, Benedik M, et al. Fibroblast growth factor 23 and left ventricular mass index in maintenance hemodialysis patients: standard versus long nocturnal hemodialysis. Ther Apher Dial. 2013;17:407–411.
   PubMed Web of Science ®Google Scholar
• Agarwal I, Ide N, Ix JH, et al. Fibroblast growth factor-23 and cardiac structure and function. J Am Heart Assoc. 2014;3:e000584.
   Google Scholar
• Sinha MD, Turner C, Booth CJ, et al. Relationship of FGF23 to indexed left ventricular mass in children with non-dialysis stages of chronic kidney disease. Pediatr Nephrol. 2015;30:1843–1852.
   PubMed Web of Science ®Google Scholar
• Shalhoub V, Shatzen EM, Ward SC, et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest. 2012;122:2543–2553.
   PubMed Web of Science ®Google Scholar
• Mirza MA, Larsson A, Melhus H, et al. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009;207:546–551.
   PubMed Web of Science ®Google Scholar
• Seiler S, Cremers B, Rebling NM, et al. The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J. 2011;32:2688–2696.
   PubMedGoogle Scholar
• Jovanovich A, Ix JH, Gottdiener J, et al. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults. Atherosclerosis. 2013;231:114–119.
   PubMed Web of Science ®Google Scholar
• Andersen IA, Huntley BK, Sandberg SS, et al. Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure. Nephrol Dial Transplant. 2016;31:767–772.
   PubMed Web of Science ®Google Scholar
• Kinoshita Y, Saito T, Shimizu Y, et al. Mutational analysis of patients with FGF23-related hypophosphatemic rickets. Eur J Endocrinol. 2012;167:165–172.
   PubMed Web of Science ®Google Scholar
• Saito T, Shimizu Y, Hori M, et al. A patient with hypophosphatemic rickets and ossification of posterior longitudinal ligament caused by a novel homozygous mutation in ENPP1 gene. Bone. 2011;49:913–916.
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Okazaki R, Shibata M, et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002;87:4957–4960.
   PubMed Web of Science ®Google Scholar
• Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–1463.
   Google Scholar
• Ishikawa J, Ishikawa S, Kabutoya T, et al. Cornell product left ventricular hypertrophy in electrocardiogram and the risk of stroke in a general population. Hypertension. 2009;53:28–34.
   PubMed Web of Science ®Google Scholar
• Nehgme R, Fahey JT, Smith C, et al. Cardiovascular abnormalities in patients with X-linked hypophosphatemia. J Clin Endocrinol Metab. 1997;82:2450–2454.
   PubMed Web of Science ®Google Scholar
• Ito N, Wijenayaka AR, Prideaux M, et al. Regulation of FGF23 expression in IDG-SW3 osteocytes and human bone by pro-inflammatory stimuli. Mol Cell Endocrinol. 2015;399:208–218.
   PubMed Web of Science ®Google Scholar
• Hori M, Kinoshita Y, Taguchi M, et al. Phosphate enhances Fgf23 expression through reactive oxygen species in UMR-106 cells. J Bone Miner Metab. 2016;34:132–139.
   PubMed Web of Science ®Google Scholar
• Leifheit-Nestler M, Grosse Siemer R, Flasbart K, et al. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol Dial Transplant. 2016;31:1088–1099.
   PubMed Web of Science ®Google Scholar
• Judd SE, Tangpricha V. Vitamin d therapy and cardiovascular health. Curr Hypertens Rep. 2011;13:187–191.
   PubMed Web of Science ®Google Scholar
• Liss Y, Frishman WH. Vitamin D: A cardioprotective agent? Cardiol Rev. 2012;20:38–44.
   PubMed Web of Science ®Google Scholar